89Zr-ibritumomab tiuxetan

N/A

Report date: 2025/11/18 17:45:25

NME

Base Information

Drug Name89Zr-ibritumomab tiuxetan

Drug Alias Name89Zr-Zevalin

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVrije Universiteit Amsterdam

China Registration ClassN/A

Develop Information

Active CompaniesVrije Universiteit Amsterdam

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A